drug conjugates
models of AML
drug development pipelines
new targeted drug
conjugate Lp
adverse drug reactions
AML patients
successful drug discovery programs
context of Acute Myeloid Leukemia Drug efficacy
targeted delivery of Lp
fast release of Lp
improved efficacy
development of antibody
promising bioactivity profile
disseminated mouse model of AML
disease models
lipoxygenase
unique bioactivity profile
pre-clinical models
successful completion
chemical entities
anticancer activity
anti-IL7R antibody
chemical biology approaches
cornerstone
narrow therapeutic windows
accurate spatiotemporal control
significant toxicity
naphthoquinone natural product-lapachone
validated biomarker
access cleavable linkers
comprehensive investigation of novel means
site
developed technology
state-of-the-art synthetic medicinal chemistry
reduced side-effects
profound implications
FDA-approved drugs
untargeted dosage forms
expression
strategies
pernicious polypharmacology
leukaemia cells
constructs
unmet medical need
average
dozens
broad applicability
project
research program
blood cancers
fact
machine learning method
leukaemiaâ€™s
allosteric modulator
deployment